The Clorox Company (CLX) Up 4.8% — Is It Time to Act?
The Clorox Company (CLX) posted a solid session on the NYSE this Friday, climbing 4.75% and adding $4.42 to close at $97.49. The move represents a meaningful bounce for a stock that has been under sustained pressure — CLX hit a 52-week high of $132.03 on July 23, 2025, and even with today's recovery, shares still sit approximately 26.2% below that peak, leaving substantial ground to reclaim. Still, the tone shifted decidedly constructive on the day, with buyers stepping in and pushing the stock steadily higher from the prior close.
Volume came in at approximately 1.27 million shares, running well below the 90-day average of roughly 2.67 million. That lighter-than-usual participation is worth noting — the session's price gain was achieved without a flood of turnover, suggesting the move was driven by selective demand rather than a broad surge of momentum-chasing activity.
Why The Clorox Company Price is Moving Higher
Today's advance in CLX is best characterized as a valuation and sentiment-driven rebound in a deeply beaten-down Consumer Staples name, rather than a response to a single fresh catalyst. The most recent hard fundamental event was Clorox's fiscal Q3 2026 earnings report in May, where the company delivered EPS of $1.64, beating estimates by approximately 5.8%, while revenue of $1.67 billion came in essentially in line with forecasts. The market's initial reaction was muted — shares moved just 0.3% in after-hours trading on the release — but that beat quietly established a floor under sentiment and built the case that the worst of the operational headwinds may be behind the company.
What's drawing buyers in now is the combination of a discounted valuation and an income profile that is increasingly difficult to ignore. With a forward P/E of approximately 15x sitting at a discount to the broader staples industry and a dividend yield above 5%, CLX has the hallmarks of a defensive value play that attracts attention when risk appetite for beaten-down names improves. The stock had fallen roughly 30.7% over the past year, underperforming its staples peer group — a decline that, for contrarian-oriented investors, begins to look like an overreaction relative to the underlying business. Analyst consensus carries an average 12-month price target near $105, with a high target approaching $163, suggesting that even the cautious consensus sees upside from current levels. Against that backdrop, today's move reflects repositioning by investors willing to look past near-term uncertainty and lean into the income and recovery story.
What is the The Clorox Company Rating - Should I Buy?
Weiss Ratings assigns CLX a C rating. Current recommendation is Hold. That assessment reflects a business with genuine operational strengths sitting alongside structural balance sheet and return concerns that prevent a more decisively bullish stance at this stage.
The standout figure in Clorox's profile is its ROE of 546.10%, which earns the Excellent Efficiency Index — an extraordinary number that reflects the heavily leveraged capital structure of a mature consumer staples operator rather than organic equity accumulation, but one that nonetheless confirms the business extracts substantial returns from its deployed asset base. A profit margin of 11.18% supports the efficiency narrative, demonstrating that Clorox's pricing power and brand portfolio translate into real bottom-line results even in a challenging cost environment. Revenue growth of 0.12% earns the Good Growth Index — modest by most standards, but not unexpected for a mature household products franchise navigating category-level demand softness.
The weaker dimensions of the Weiss profile deserve equal attention. The Weak Solvency Index reflects the leverage embedded in that capital structure — a meaningful risk consideration if interest rates remain elevated or if operational cash flows compress. The Weak Total Return Index flags that shareholders have not been rewarded from a total return standpoint over the measured period, consistent with the stock's steep year-over-year decline. The Weak Volatility Index rounds out the cautionary picture, indicating that CLX has experienced meaningful price swings — something the Weak Volatility Index flags as a risk factor for investors who prioritize stability. Together, these metrics explain why the Hold rating is appropriate: the business has enough going for it to avoid a Sell, but the headwinds are real enough to stop short of a Buy.
Within the Consumer Staples sector, Clorox is on par with The Procter & Gamble Company (PG, C), Church & Dwight Co., Inc. (CHD, C), and Kenvue Inc. (KVUE, C), while ranking below Colgate-Palmolive Company (CL, C+) and above Kimberly-Clark Corporation (KMB, C-). That positioning places Clorox squarely in the middle of the peer group — a reasonable reflection of a brand-driven business working through a difficult stretch without the balance sheet flexibility or top-line momentum to stand out among its Consumer Staples competitors.
About The Clorox Company
The Clorox Company (CLX) is a Consumer Staples company built around a portfolio of everyday brands that hold entrenched positions in cleaning, disinfecting, and personal care categories. The company's flagship Clorox bleach and disinfecting products franchise remains one of the most recognized names in household cleaning, with a track record of consumer trust and category leadership that competitors have struggled to dislodge. That brand equity translates into shelf placement, retailer relationships, and consumer repurchase behavior that underpin the business's durability across economic cycles.
Beyond its core cleaning segment, Clorox operates across several adjacent product categories through brands including Glad trash bags, Hidden Valley dressings and sauces, Burt's Bees natural personal care products, and Kingsford charcoal, among others. This diversification across household and lifestyle categories reduces dependence on any single product line and gives the company multiple levers for revenue management as consumer preferences evolve. Burt's Bees in particular represents Clorox's exposure to the growing natural and wellness segment, where premium pricing dynamics differ meaningfully from the mass-market cleaning categories that anchor the rest of the portfolio.
Clorox's competitive position is reinforced by decades of manufacturing expertise, a well-established supply chain, and proprietary formulations that are difficult to replicate at comparable scale and quality. The company competes in categories where trust, safety, and efficacy are paramount — attributes that sustain pricing power and limit the effectiveness of private-label competition in a way that more commoditized product categories do not. Its long history of brand investment and product development has created customer loyalty patterns that support consistent demand even when macroeconomic conditions soften.
Investor Outlook
The Clorox Company (CLX) carries a Weiss Rating of C (Hold), reflecting a business with durable brand assets and solid margins navigating a period of elevated leverage and subdued top-line growth. Investors will want to monitor the pace of balance sheet deleveraging, any signs of volume recovery in core cleaning categories, and whether management's execution continues to support the earnings trajectory that fiscal Q3 2026 hinted at. See full rankings of all C-rated Consumer Staples stocks inside the Weiss Stock Screener.
--